drugset / Trial / NCT00888914

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00888914 ↗

Phase 2 Completed 60 enrolled Revance Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of RT001 to treat moderate to severe lateral canthal lines in adults.

Timeline

Start
2008-11
Primary completion
2009-01
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator RT001 Protein / enzyme biologic — Topical

Indications